Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give signed agreement to take part and follow the study's requirements
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), either by tissue sample or by specific liver scan results on CT or MRI
• People whose liver cancer is at an advanced stage (BCLC Stage C), or at an intermediate stage (BCLC Stage B) where standard treatments have not worked, were refused, or could not be tolerated
• People who have tumour tissue from a sample taken within the last 2 years, or who agree to have a tissue sample taken at the start of the study
• People who are older than 20 years of age when joining the study
• People whose general health and ability to carry out daily activities meets a specific level (ECOG score of 0 or 1, meaning generally active with little or no limitation)
• People whose liver function meets a specific standard (Child-Pugh class A or B7)
• People who have at least one measurable tumour in the liver, as assessed by standard imaging criteria
• People who weigh more than 30 kg
• People whose blood counts and organ function meet the required levels, including healthy enough red blood cells, white blood cells, and platelets, and adequate liver and kidney function
• Women who are post-menopausal or who have a negative pregnancy test before starting the study
• People who are willing and able to attend all required visits, treatments, and follow-up appointments for the full duration of the study
• People who have a life expectancy of at least 12 weeks

Who may not be able to join:

• People whose liver cancer is a specific rare subtype called fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma
• People whose lung scan results from a specific procedure show more than 30% flow to the lungs (confirm with trial site)
• People who are currently enrolled in another interventional clinical trial (observational studies or follow-up phases of other trials may be acceptable)
• People who received their last cancer treatment less than 14 days before the first dose of the study drug, or who have not had a long enough break from a previous treatment
• People who still have significant side effects (grade 2 or higher) from a previous cancer treatment, with some exceptions such as hair loss or skin colour changes
• People who are currently receiving any other chemotherapy, biological therapy, or hormonal therapy for cancer (hormonal therapy for non-cancer reasons may be acceptable)
• People who had a major surgical procedure within 28 days before the first dose of the study treatment
• People with serious uncontrolled illnesses, such as active infections (other than hepatitis B or C), heart failure, uncontrolled high blood pressure, unstable chest pain, irregular heartbeat, lung disease, serious ongoing digestive conditions with diarrhoea, or significant mental health or social situations that could affect safe participation
• People with a history of another primary cancer, except for specific conditions listed in the study protocol (confirm with trial site)
• People with a history of cancer spreading to the lining around the brain or spinal cord
• People who have cancer that has spread to the brain or is pressing on the spinal cord
• People with a history of a primary immune deficiency condition
• People with an active infection, including tuberculosis
• Women who are pregnant or breastfeeding, or people of reproductive age who are not willing to use effective contraception from the screening period until 90 days after the last dose of the study treatment
• People with a known allergy or sensitivity to any of the study drugs or their ingredients

Important: Always verify eligibility with the trial site directly before applying.